2.2.0.7 false Subsequent Event 0215 - Disclosure - Subsequent Event true false false false 1 USD false false USD Standard http://www.xbrl.org/2003/iso4217 USD iso4217 0 USDEPS Divide http://www.xbrl.org/2003/iso4217 USD iso4217 http://www.xbrl.org/2003/instance shares xbrli 0 $ 2 Subsequent Event [Abstract] 0 kg_SubsequentEventAbstract kg false na duration Subsequent Event. false false false false false true false false false false false false 1 false false false false 0 0 false false false xbrli:stringItemType string Subsequent Event. false 3 Subsequent Event 1 us-gaap_ScheduleOfSubsequentEventsTextBlock us-gaap true na duration No definition available. false false false false false false false false false false false verboselabel false 1 false false false false 0 0   <div style="margin-left: 0%"> <div style="margin-top: 12pt; font-size: 1pt">  </div> <div align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent"> <b><font style="font-family: 'Times New Roman', Times">15. Subsequent Event</font></b> </div> <div style="margin-top: 6pt; font-size: 1pt">  </div> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent"> On October 11, 2010, King entered into an agreement and plan of merger (the “Merger Agreement”) with Pfizer pursuant to which Pfizer has agreed to commence a tender offer to purchase all of the outstanding shares of common stock, no par value per share, of King (the “Shares”) for $14.25 per Share net to the seller in cash (the “Offer”). Pfizer commenced the Offer on October 22, 2010. The Offer expires on November 19, 2010, unless extended in accordance with the terms of the Merger Agreement. Completion of the Offer is subject to customary conditions including, among others, (i) a majority of the Shares issued and outstanding (on a fully-diluted basis, without giving effect to compensatory equity awards that may be validly cancelled under the Merger Agreement upon completion of the Offer) being validly tendered and not validly withdrawn and (ii) the applicable waiting period under the <font style="white-space: nowrap">Hart-Scott-Rodino</font> Antitrust Improvements Act of 1976, as amended, expiring and all other authorizations, consents, and approvals of or notices or filings with any foreign antitrust or competition regulatory authority having been made or obtained. </div> <div style="margin-top: 6pt; font-size: 1pt">  </div> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent"> Subject to the terms and conditions of the Merger Agreement, King has granted Pfizer an irrevocable option (the <font style="white-space: nowrap">“Top-Up</font> Option”) to purchase an aggregate number of newly-issued shares of King common stock that, at the time of such exercise, and when added to the Shares owned by Pfizer or any of its subsidiaries, constitutes one Share more than 90% of the Shares that would be outstanding immediately after the issuance of Shares pursuant to such exercise (on a fully diluted basis), subject to there being authorized Shares available for issuance. The <font style="white-space: nowrap">Top-Up</font> Option is exercisable only after Shares have been purchased by Pfizer pursuant to the Offer. The consideration for each Share acquired upon exercise of the <font style="white-space: nowrap">Top-Up</font> Option will be the Offer price. </div>  </div>   <div style="margin-left: 0%">  <div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent"> <b> <font style="font-family: 'Times New Roman', Times"> </font> </b> </div> <div style="margin-top: 0pt; font-size: 1pt"> </div> <div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent"> <b> <font style="font-family: 'Times New Roman', Times"> </font> </b> </div>  <div style="margin-top: 6pt; font-size: 1pt">  </div> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent"> The Merger Agreement prohibits King from soliciting or initiating discussions with third parties regarding other proposals to acquire King and King has agreed to restrictions on its ability to respond to such proposals, subject to certain exceptions. The Merger Agreement also contains customary termination provisions for King and Pfizer. Upon termination of the Merger Agreement, under specified circumstances King will be required to pay to Pfizer a termination fee of $110 million (or $75 million if the basis for the actions giving rise to such termination was King’s receipt, within 30 days of the date of the Merger Agreement, of an alternative acquisition proposal that King’s Board of Directors determines in good faith constitutes or could be reasonably expected to result in a superior proposal). In addition, the Merger Agreement contains representations, warranties and covenants of the parties customary for transactions of this type. </div> <div style="margin-top: 6pt; font-size: 1pt">  </div> <div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent"> In connection with the Merger Agreement, in October 2010 the Board of Directors approved payments of awards under certain of King’s employee incentive award plans for the 2010 performance period, which will be recognized and paid in the fourth quarter of 2010. In addition, the Company expects to incur fees for its legal and financial advisors related to the merger with Pfizer. In the aggregate, the costs described in this paragraph are estimated to approximate $50 to $60 million. </div> </div>  <!-- Begin Block Tagged Note false false false us-types:textBlockItemType textblock Describes disclosed significant events or transactions that occurred after the balance sheet date, but before the issuance of the financial statements. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 11 false 1 2 false UnKnown UnKnown UnKnown false true